speb/financial-data huggingface dataset:
GSK income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -45826239.70
GSK income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
GSK income_statement (annual, 2025-12-31) — Tax Provision: 1112000000.00
GSK income_statement (quarterly, 2025-12-31) — Tax Provision: 223000000.00
GSK income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.15
GSK income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.23
GSK balance_sheet (annual, 2025-12-31) — Taxes Receivable: 799000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 799000000.00
GSK cash_flow (annual, 2025-12-31) — Taxes Refund Paid: -1202000000.00
GSK cash_flow (quarterly, 2025-12-31) — Taxes Refund Paid: -411000000.00
GSK balance_sheet (annual, 2025-12-31) — Total Assets: 61118000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Total Assets: 61118000000.00
GSK balance_sheet (annual, 2025-12-31) — Total Capitalization: 30392000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 30392000000.00
GSK balance_sheet (annual, 2025-12-31) — Total Debt: 17720000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Total Debt: 17720000000.00
GSK balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 15956000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 15956000000.00
GSK income_statement (annual, 2025-12-31) — Total Expenses: 24329000000.00
GSK income_statement (quarterly, 2025-12-31) — Total Expenses: 7112000000.00
GSK balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 45162000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 45162000000.00
GSK balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 43608000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 43608000000.00
GSK balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 23771000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 23771000000.00
GSK income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 7932000000.00
GSK income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 1100000000.00
GSK income_statement (annual, 2025-12-31) — Total Other Finance Cost: 2000000.00
GSK balance_sheet (annual, 2025-12-31) — Total Tax Payable: 498000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 498000000.00
GSK income_statement (annual, 2025-12-31) — Total Unusual Items: -305000000.00
GSK income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -305000000.00
GSK balance_sheet (annual, 2025-12-31) — Tradeand Other Payables Non Current: 896000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Tradeand Other Payables Non Current: 896000000.00
GSK balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 302894704.00
GSK balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 302894704.00
GSK balance_sheet (annual, 2025-12-31) — Work In Process: 3699000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Work In Process: 3699000000.00
GSK balance_sheet (annual, 2025-12-31) — Working Capital: -3881000000.00
GSK balance_sheet (quarterly, 2025-12-31) — Working Capital: -3881000000.00
GSK income_statement (quarterly, 2026-03-31) — +Operating Expense: 3461000000.00
GSK income_statement (quarterly, 2026-03-31) — +Total Revenue: 7629000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 14335000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 7756000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 3506000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 138000000.00
GSK income_statement (quarterly, 2026-03-31) — Basic Average Shares: 2011500000.00
GSK income_statement (quarterly, 2026-03-31) — Basic EPS: 0.86
GSK cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 3250000000.00
GSK cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -443000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Capital Stock: 1349000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 3442000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 3443000000.00
GSK cash_flow (quarterly, 2026-03-31) — Cash Dividends Paid: -643000000.00
GSK cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -1082000000.00
GSK cash_flow (quarterly, 2026-03-31) — Changes In Cash: -53000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Common Stock: 1349000000.00
GSK cash_flow (quarterly, 2026-03-31) — Common Stock Dividend Paid: -643000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 17852000000.00
GSK cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 8000000.00
GSK cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -326000000.00
GSK income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 1875000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Current Assets: 17761000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 5044000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 22429000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Current Provisions: 908000000.00
GSK cash_flow (quarterly, 2026-03-31) — Deferred Tax: 305000000.00
GSK cash_flow (quarterly, 2026-03-31) — Depreciation: 463000000.00
GSK cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 463000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Derivative Product Liabilities: 56000000.00
GSK income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 2037000000.00
GSK income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.85
GSK income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 1737000000.00
GSK income_statement (quarterly, 2026-03-31) — EBIT: 2311000000.00
GSK income_statement (quarterly, 2026-03-31) — EBITDA: 2774000000.00
GSK cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 2000000.00
GSK cash_flow (quarterly, 2026-03-31) — End Cash Position: 3199000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Financial Assets: 19000000.00
GSK cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 272000000.00
GSK cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 698000000.00
GSK income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 2119000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Goodwill: 7287000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 25425000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Gross PPE: 10038000000.00
GSK income_statement (quarterly, 2026-03-31) — Gross Profit: 5754000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 86000000.00
GSK income_statement (quarterly, 2026-03-31) — Interest Expense: 167000000.00
GSK income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 167000000.00
GSK income_statement (quarterly, 2026-03-31) — Interest Income: 22000000.00
GSK income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 22000000.00
GSK cash_flow (quarterly, 2026-03-31) — Interest Paid Cff: -85000000.00
GSK cash_flow (quarterly, 2026-03-31) — Interest Received Cfi: 45000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Inventory: 6157000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Invested Capital: 17852000000.00
GSK cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -1466000000.00
GSK cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 8000000.00
GSK cash_flow (quarterly, 2026-03-31) — Issuance Of Debt: 1202000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 14012000000.00
GSK cash_flow (quarterly, 2026-03-31) — Long Term Debt Issuance: 0.00
GSK balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 99000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 579000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Minority Interest: -430000000.00
GSK income_statement (quarterly, 2026-03-31) — Minority Interests: -102000000.00
GSK cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: -1166000000.00
GSK cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -318000000.00
GSK income_statement (quarterly, 2026-03-31) — Net Income: 1737000000.00
GSK income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 1737000000.00
GSK income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 1839000000.00
GSK income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 1737000000.00
GSK income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 1737000000.00
GSK cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 1839000000.00
GSK income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 1839000000.00
GSK cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: -160000000.00
GSK income_statement (quarterly, 2026-03-31) — Net Interest Income: -145000000.00
GSK cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 9000000.00
GSK cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: 1182000000.00
GSK cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: 0.00
GSK income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -145000000.00
GSK cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: 1703000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Net PPE: 10038000000.00
GSK cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -194000000.00
GSK cash_flow (quarterly, 2026-03-31) — Net Short Term Debt Issuance: 1182000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: -7573000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 6307000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 292000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 1695000000.00
GSK income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 2774000000.00
GSK income_statement (quarterly, 2026-03-31) — Normalized Income: 1737000000.00
GSK cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 1141000000.00
GSK income_statement (quarterly, 2026-03-31) — Operating Income: 2293000000.00
GSK income_statement (quarterly, 2026-03-31) — Operating Revenue: 7629000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 4020267166.00
GSK balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 1395000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 18138000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Other Investments: 859000000.00
GSK cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 145000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 2361000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 6318000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Other Properties: 10038000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 1000000.00
GSK income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
GSK balance_sheet (quarterly, 2026-03-31) — Payables: 14890000000.00
GSK income_statement (quarterly, 2026-03-31) — Pretax Income: 2144000000.00
GSK cash_flow (quarterly, 2026-03-31) — Purchase Of Business: -1414000000.00
GSK cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: -222000000.00
GSK cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -221000000.00
GSK income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 1875000000.00
GSK income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 463000000.00
GSK cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -20000000.00
GSK cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -326000000.00
GSK income_statement (quarterly, 2026-03-31) — Research And Development: 1692000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 11590000000.00
GSK cash_flow (quarterly, 2026-03-31) — Sale Of Business: 248000000.00
GSK cash_flow (quarterly, 2026-03-31) — Sale Of Intangibles: 62000000.00
GSK cash_flow (quarterly, 2026-03-31) — Sale Of PPE: 27000000.00
GSK income_statement (quarterly, 2026-03-31) — Selling General And Administration: 2119000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Share Issued: 4316179781.00
GSK cash_flow (quarterly, 2026-03-31) — Short Term Debt Issuance: 1202000000.00
GSK cash_flow (quarterly, 2026-03-31) — Short Term Debt Payments: -20000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 17852000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: -7573000000.00
GSK income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
GSK income_statement (quarterly, 2026-03-31) — Tax Provision: 305000000.00
GSK income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.14
GSK balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 181000000.00
GSK cash_flow (quarterly, 2026-03-31) — Taxes Refund Paid: -209000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Total Assets: 62869000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 17852000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Total Debt: 19056000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 17422000000.00
GSK income_statement (quarterly, 2026-03-31) — Total Expenses: 5336000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 45447000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 45108000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 23018000000.00
GSK income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 2293000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 555000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Tradeand Other Payables Non Current: 66000000.00
GSK balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 295912615.00
GSK balance_sheet (quarterly, 2026-03-31) — Working Capital: -4668000000.00
GSK.L balance_sheet (annual, 2021-12-31) — Allowance For Doubtful Accounts Receivable: -150000000.00
GSK.L balance_sheet (annual, 2021-12-31) — Derivative Product Liabilities: 1000000.00
GSK.L cash_flow (annual, 2021-12-31) — Gain Loss On Investment Securities: -8000000.00
GSK.L income_statement (annual, 2021-12-31) — Net Income Discontinuous Operations: 1580000000.00
GSK.L cash_flow (annual, 2021-12-31) — Net Other Investing Changes: -122000000.00
GSK.L income_statement (annual, 2021-12-31) — Rent Expense Supplemental: 20000000.00
GSK.L cash_flow (annual, 2021-12-31) — Sale Of Investment: 18000000.00
GSK.L income_statement (annual, 2022-12-31) — +Operating Expense: 13041000000.00
GSK.L income_statement (annual, 2022-12-31) — +Total Revenue: 29324000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Accounts Payable: 3866000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Accounts Receivable: 5452000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -10518000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 3440000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -91000000.00
GSK.L cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 1086000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Assets Held For Sale Current: 98000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Available For Sale Securities: 1174000000.00
GSK.L income_statement (annual, 2022-12-31) — Basic Average Shares: 4026000000.00
GSK.L income_statement (annual, 2022-12-31) — Basic EPS: 3.71
GSK.L cash_flow (annual, 2022-12-31) — Beginning Cash Position: 3819000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 561000000.00
GSK.L cash_flow (annual, 2022-12-31) — Capital Expenditure: -2258000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 1008000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Capital Stock: 1347000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 3523000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 7677000000.00
GSK.L cash_flow (annual, 2022-12-31) — Cash Dividends Paid: -3467000000.00
GSK.L cash_flow (annual, 2022-12-31) — Change In Inventory: -269000000.00
GSK.L cash_flow (annual, 2022-12-31) — Change In Other Current Assets: -962000000.00
GSK.L cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: 1628000000.00
GSK.L cash_flow (annual, 2022-12-31) — Change In Payable: 489000000.00
GSK.L cash_flow (annual, 2022-12-31) — Change In Receivables: -616000000.00
GSK.L cash_flow (annual, 2022-12-31) — Change In Working Capital: 270000000.00
GSK.L cash_flow (annual, 2022-12-31) — Changes In Cash: -546000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Common Stock: 1347000000.00
GSK.L cash_flow (annual, 2022-12-31) — Common Stock Dividend Paid: -3467000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Common Stock Equity: 10598000000.00
GSK.L cash_flow (annual, 2022-12-31) — Common Stock Issuance: 25000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Construction In Progress: 1850000000.00
GSK.L income_statement (annual, 2022-12-31) — Cost Of Revenue: 9554000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Current Assets: 20769000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 167000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Current Debt: 3785000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 3952000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Current Liabilities: 22810000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Current Provisions: 652000000.00
GSK.L cash_flow (annual, 2022-12-31) — Deferred Tax: 707000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Defined Pension Benefit: 229000000.00
GSK.L cash_flow (annual, 2022-12-31) — Depreciation: 1061000000.00
GSK.L cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 2147000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Derivative Product Liabilities: 0.00
GSK.L income_statement (annual, 2022-12-31) — Diluted Average Shares: 4084000000.00
GSK.L income_statement (annual, 2022-12-31) — Diluted EPS: 3.66
GSK.L income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 14956000000.00
GSK.L cash_flow (annual, 2022-12-31) — Dividends Received Cfi: 6000000.00
GSK.L income_statement (annual, 2022-12-31) — EBIT: 6454000000.00
GSK.L income_statement (annual, 2022-12-31) — EBITDA: 8601000000.00
GSK.L cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: 152000000.00
GSK.L cash_flow (annual, 2022-12-31) — End Cash Position: 3425000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Financial Assets: 0.00
GSK.L balance_sheet (annual, 2022-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 327000000.00
GSK.L cash_flow (annual, 2022-12-31) — Financing Cash Flow: 823000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Finished Goods: 1284000000.00
GSK.L cash_flow (annual, 2022-12-31) — Free Cash Flow: 5145000000.00
GSK.L cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: -1000000.00
GSK.L cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of Business: -36000000.00
GSK.L cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: -185000000.00
GSK.L income_statement (annual, 2022-12-31) — General And Administrative Expense: 8372000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Goodwill: 7046000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 21364000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 5543000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Gross PPE: 20138000000.00
GSK.L income_statement (annual, 2022-12-31) — Gross Profit: 19770000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Hedging Assets Current: 190000000.00
GSK.L income_statement (annual, 2022-12-31) — Interest Expense: 826000000.00
GSK.L income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 826000000.00
GSK.L income_statement (annual, 2022-12-31) — Interest Income: 31000000.00
GSK.L income_statement (annual, 2022-12-31) — Interest Income Non Operating: 31000000.00
GSK.L cash_flow (annual, 2022-12-31) — Interest Paid Cff: -848000000.00
GSK.L cash_flow (annual, 2022-12-31) — Interest Received Cfi: 64000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Inventory: 5146000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Invested Capital: 30577000000.00
GSK.L cash_flow (annual, 2022-12-31) — Investing Cash Flow: -8772000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Investmentin Financial Assets: 1501000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Investmentsin Associatesat Cost: 64000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Investmentsin Joint Venturesat Cost: 10000000.00
GSK.L cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 25000000.00
GSK.L cash_flow (annual, 2022-12-31) — Issuance Of Debt: 2046000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Land And Improvements: 6648000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 841000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Long Term Debt: 16194000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 17035000000.00
GSK.L cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 1025000000.00
GSK.L cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -6668000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Long Term Equity Investment: 74000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Long Term Provisions: 532000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 11073000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Minority Interest: -502000000.00
GSK.L income_statement (annual, 2022-12-31) — Minority Interests: -665000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: -3136000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 25000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Net Debt: 16456000000.00
GSK.L income_statement (annual, 2022-12-31) — Net Income: 14956000000.00
GSK.L income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 14956000000.00
GSK.L income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 4921000000.00
GSK.L income_statement (annual, 2022-12-31) — Net Income Discontinuous Operations: 10700000000.00
GSK.L income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 14956000000.00
GSK.L income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 4256000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 4921000000.00
GSK.L income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 15621000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -919000000.00
GSK.L income_statement (annual, 2022-12-31) — Net Interest Income: -826000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: 1000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -4622000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -5643000000.00
GSK.L income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -826000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net Other Financing Charges: 10458000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net Other Investing Changes: -3791000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Net PPE: 9620000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -997000000.00
GSK.L cash_flow (annual, 2022-12-31) — Net Short Term Debt Issuance: 1021000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Net Tangible Assets: -10766000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Non Current Accrued Expenses: 11000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Non Current Deferred Revenue: 83000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 5658000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 289000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 2579000000.00
GSK.L income_statement (annual, 2022-12-31) — Normalized EBITDA: 8874000000.00
GSK.L income_statement (annual, 2022-12-31) — Normalized Income: 4494602000.00
GSK.L cash_flow (annual, 2022-12-31) — Operating Cash Flow: 7403000000.00
GSK.L income_statement (annual, 2022-12-31) — Operating Income: 6729000000.00
GSK.L income_statement (annual, 2022-12-31) — Operating Revenue: 29324000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 4094218581.00
GSK.L balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 1289000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Other Equity Interest: -353000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 14318000000.00
GSK.L cash_flow (annual, 2022-12-31) — Other Non Cash Items: 350000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 5779000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Other Payable: 418000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Other Properties: 6000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Other Receivables: 766000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 4154000000.00
GSK.L income_statement (annual, 2022-12-31) — Other Special Charges: -376000000.00
GSK.L income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 0.00
GSK.L balance_sheet (annual, 2022-12-31) — Payables: 4755000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 126000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Prepaid Assets: 343000000.00
GSK.L income_statement (annual, 2022-12-31) — Pretax Income: 5628000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Properties: 0.00
GSK.L cash_flow (annual, 2022-12-31) — Purchase Of Business: -3374000000.00
GSK.L cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -1115000000.00
GSK.L cash_flow (annual, 2022-12-31) — Purchase Of PPE: -1143000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Raw Materials: 1576000000.00
GSK.L income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 9554000000.00
GSK.L income_statement (annual, 2022-12-31) — Reconciled Depreciation: 2147000000.00
GSK.L income_statement (annual, 2022-12-31) — Rent Expense Supplemental: 17000000.00
GSK.L cash_flow (annual, 2022-12-31) — Repayment Of Debt: -6668000000.00
GSK.L income_statement (annual, 2022-12-31) — Research And Development: 5488000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Restricted Cash: 200000000.00
GSK.L income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 1607000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Retained Earnings: 4363000000.00
GSK.L cash_flow (annual, 2022-12-31) — Sale Of Business: 238000000.00
GSK.L cash_flow (annual, 2022-12-31) — Sale Of Intangibles: 196000000.00
GSK.L cash_flow (annual, 2022-12-31) — Sale Of Investment: 1000000.00
GSK.L cash_flow (annual, 2022-12-31) — Sale Of PPE: 146000000.00
GSK.L income_statement (annual, 2022-12-31) — Selling General And Administration: 8372000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Share Issued: 4311343341.00
GSK.L cash_flow (annual, 2022-12-31) — Short Term Debt Issuance: 1021000000.00
GSK.L cash_flow (annual, 2022-12-31) — Short Term Debt Payments: 0.00
GSK.L income_statement (annual, 2022-12-31) — Special Income Charges: -1231000000.00
GSK.L cash_flow (annual, 2022-12-31) — Stock Based Compensation: 346000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Stockholders Equity: 10598000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Tangible Book Value: -10766000000.00
GSK.L income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: -34398000.00
GSK.L income_statement (annual, 2022-12-31) — Tax Provision: 707000000.00
GSK.L income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.13
GSK.L balance_sheet (annual, 2022-12-31) — Taxes Receivable: 897000000.00
GSK.L cash_flow (annual, 2022-12-31) — Taxes Refund Paid: -1310000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Total Assets: 60146000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Total Capitalization: 26792000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Total Debt: 20987000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 10096000000.00
GSK.L income_statement (annual, 2022-12-31) — Total Expenses: 22595000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 50050000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 39377000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 27240000000.00
GSK.L income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 6433000000.00
GSK.L income_statement (annual, 2022-12-31) — Total Other Finance Cost: 31000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Total Tax Payable: 471000000.00
GSK.L income_statement (annual, 2022-12-31) — Total Unusual Items: -273000000.00
GSK.L income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -273000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Tradeand Other Payables Non Current: 932000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Treasury Shares Number: 217124760.00
GSK.L balance_sheet (annual, 2022-12-31) — Work In Process: 2286000000.00
GSK.L balance_sheet (annual, 2022-12-31) — Working Capital: -2041000000.00
GSK.L income_statement (annual, 2023-12-31) — +Operating Expense: 14418000000.00
GSK.L income_statement (annual, 2023-12-31) — +Total Revenue: 30328000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Accounts Payable: 3717000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Accounts Receivable: 5905000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -10259000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 3451000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -85000000.00
GSK.L cash_flow (annual, 2023-12-31) — Amortization Cash Flow: 1212000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Assets Held For Sale Current: 76000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Available For Sale Securities: 940000000.00
GSK.L income_statement (annual, 2023-12-31) — Basic Average Shares: 4052000000.00
GSK.L income_statement (annual, 2023-12-31) — Basic EPS: 1.22
GSK.L cash_flow (annual, 2023-12-31) — Beginning Cash Position: 3425000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 751000000.00
GSK.L cash_flow (annual, 2023-12-31) — Capital Expenditure: -2344000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 1207000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Capital Stock: 1348000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 2746000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 4992000000.00
GSK.L cash_flow (annual, 2023-12-31) — Cash Dividends Paid: -2247000000.00
GSK.L cash_flow (annual, 2023-12-31) — Change In Inventory: -424000000.00
GSK.L cash_flow (annual, 2023-12-31) — Change In Other Current Assets: -457000000.00
GSK.L cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: 492000000.00
GSK.L cash_flow (annual, 2023-12-31) — Change In Payable: 674000000.00
GSK.L cash_flow (annual, 2023-12-31) — Change In Receivables: -649000000.00
GSK.L cash_flow (annual, 2023-12-31) — Change In Working Capital: -364000000.00
GSK.L cash_flow (annual, 2023-12-31) — Changes In Cash: -468000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Common Stock: 1348000000.00
GSK.L cash_flow (annual, 2023-12-31) — Common Stock Dividend Paid: -2247000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Common Stock Equity: 13347000000.00
GSK.L cash_flow (annual, 2023-12-31) — Common Stock Issuance: 10000000.00
GSK.L cash_flow (annual, 2023-12-31) — Common Stock Payments: 0.00
GSK.L balance_sheet (annual, 2023-12-31) — Construction In Progress: 2120000000.00
GSK.L income_statement (annual, 2023-12-31) — Cost Of Revenue: 8565000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Current Assets: 18644000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 156000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Current Debt: 2657000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 2813000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Current Liabilities: 21068000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Current Provisions: 744000000.00
GSK.L cash_flow (annual, 2023-12-31) — Deferred Tax: 756000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Defined Pension Benefit: 634000000.00
GSK.L cash_flow (annual, 2023-12-31) — Depreciation: 1082000000.00
GSK.L cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 2294000000.00
GSK.L income_statement (annual, 2023-12-31) — Diluted Average Shares: 4111000000.00
GSK.L income_statement (annual, 2023-12-31) — Diluted EPS: 1.20
GSK.L income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: 4928000000.00
GSK.L cash_flow (annual, 2023-12-31) — Dividends Received Cfi: 231000000.00
GSK.L income_statement (annual, 2023-12-31) — EBIT: 6789000000.00
GSK.L income_statement (annual, 2023-12-31) — EBITDA: 9083000000.00
GSK.L cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -99000000.00
GSK.L cash_flow (annual, 2023-12-31) — End Cash Position: 2858000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Financial Assets: 0.00
GSK.L balance_sheet (annual, 2023-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 224000000.00
GSK.L cash_flow (annual, 2023-12-31) — Financing Cash Flow: -5641000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Finished Goods: 1455000000.00
GSK.L cash_flow (annual, 2023-12-31) — Free Cash Flow: 4424000000.00
GSK.L cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of Business: -1000000.00
GSK.L cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: -12000000.00
GSK.L income_statement (annual, 2023-12-31) — General And Administrative Expense: 9385000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Goodwill: 6811000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 21579000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Gross Accounts Receivable: 5990000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Gross PPE: 20216000000.00
GSK.L income_statement (annual, 2023-12-31) — Gross Profit: 21763000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Hedging Assets Current: 130000000.00
GSK.L income_statement (annual, 2023-12-31) — Interest Expense: 725000000.00
GSK.L income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 725000000.00
GSK.L income_statement (annual, 2023-12-31) — Interest Income: 48000000.00
GSK.L income_statement (annual, 2023-12-31) — Interest Income Non Operating: 48000000.00
GSK.L cash_flow (annual, 2023-12-31) — Interest Paid Cff: -766000000.00
GSK.L cash_flow (annual, 2023-12-31) — Interest Received Cfi: 115000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Inventory: 5498000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Invested Capital: 30158000000.00
GSK.L cash_flow (annual, 2023-12-31) — Investing Cash Flow: -1595000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 1164000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Investmentsin Associatesat Cost: 55000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Investmentsin Joint Venturesat Cost: 0.00
GSK.L cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 10000000.00
GSK.L cash_flow (annual, 2023-12-31) — Issuance Of Debt: 223000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Land And Improvements: 6455000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 1051000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Long Term Debt: 14154000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 15205000000.00
GSK.L cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 223000000.00
GSK.L cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -2260000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Long Term Equity Investment: 55000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Long Term Provisions: 495000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 10886000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Minority Interest: -552000000.00
GSK.L income_statement (annual, 2023-12-31) — Minority Interests: -380000000.00
GSK.L cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 291000000.00
GSK.L cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 10000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Net Debt: 14065000000.00
GSK.L income_statement (annual, 2023-12-31) — Net Income: 4928000000.00
GSK.L income_statement (annual, 2023-12-31) — Net Income Common Stockholders: 4928000000.00
GSK.L income_statement (annual, 2023-12-31) — Net Income Continuous Operations: 5308000000.00
GSK.L income_statement (annual, 2023-12-31) — Net Income Discontinuous Operations: 0.00
GSK.L income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: 4928000000.00
GSK.L income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: 4928000000.00
GSK.L cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: 5308000000.00
GSK.L income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: 5308000000.00
GSK.L cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -1018000000.00
GSK.L income_statement (annual, 2023-12-31) — Net Interest Income: -735000000.00
GSK.L cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 72000000.00
GSK.L cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -2370000000.00
GSK.L cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -2037000000.00
GSK.L income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -735000000.00
GSK.L cash_flow (annual, 2023-12-31) — Net Other Financing Charges: 341000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Net PPE: 9957000000.00
GSK.L cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -1286000000.00
GSK.L cash_flow (annual, 2023-12-31) — Net Short Term Debt Issuance: -333000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Net Tangible Assets: -8232000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Non Current Accrued Expenses: 4000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Non Current Deferred Revenue: 254000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 6049000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 311000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 2340000000.00
GSK.L income_statement (annual, 2023-12-31) — Normalized EBITDA: 9624000000.00
GSK.L income_statement (annual, 2023-12-31) — Normalized Income: 5401375000.00
GSK.L cash_flow (annual, 2023-12-31) — Operating Cash Flow: 6768000000.00
GSK.L income_statement (annual, 2023-12-31) — Operating Income: 7345000000.00
GSK.L income_statement (annual, 2023-12-31) — Operating Revenue: 30328000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 4056260617.00
GSK.L balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 1053000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Other Equity Interest: -288000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 14768000000.00
GSK.L cash_flow (annual, 2023-12-31) — Other Non Cash Items: 470000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 5609000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Other Payable: 346000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Other Properties: 4000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Other Receivables: 560000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 2246000000.00
GSK.L income_statement (annual, 2023-12-31) — Other Special Charges: -87000000.00
GSK.L income_statement (annual, 2023-12-31) — Otherunder Preferred Stock Dividend: 0.00
GSK.L balance_sheet (annual, 2023-12-31) — Payables: 4563000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 126000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Prepaid Assets: 355000000.00
GSK.L income_statement (annual, 2023-12-31) — Pretax Income: 6064000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Properties: 0.00
GSK.L cash_flow (annual, 2023-12-31) — Purchase Of Business: -1591000000.00
GSK.L cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -1030000000.00
GSK.L cash_flow (annual, 2023-12-31) — Purchase Of PPE: -1314000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Raw Materials: 1594000000.00
GSK.L income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 8565000000.00
GSK.L income_statement (annual, 2023-12-31) — Reconciled Depreciation: 2294000000.00
GSK.L income_statement (annual, 2023-12-31) — Rent Expense Supplemental: 27000000.00
GSK.L cash_flow (annual, 2023-12-31) — Repayment Of Debt: -2593000000.00
GSK.L cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: 0.00
GSK.L income_statement (annual, 2023-12-31) — Research And Development: 6223000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Restricted Cash: 190000000.00
GSK.L income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: 791000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Retained Earnings: 7239000000.00
GSK.L cash_flow (annual, 2023-12-31) — Sale Of Business: 1882000000.00
GSK.L cash_flow (annual, 2023-12-31) — Sale Of Intangibles: 12000000.00
GSK.L cash_flow (annual, 2023-12-31) — Sale Of Investment: 72000000.00
GSK.L cash_flow (annual, 2023-12-31) — Sale Of PPE: 28000000.00
GSK.L income_statement (annual, 2023-12-31) — Selling General And Administration: 9385000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Share Issued: 4312145983.00
GSK.L cash_flow (annual, 2023-12-31) — Short Term Debt Issuance: 0.00
GSK.L cash_flow (annual, 2023-12-31) — Short Term Debt Payments: -333000000.00
GSK.L income_statement (annual, 2023-12-31) — Special Income Charges: -704000000.00
GSK.L cash_flow (annual, 2023-12-31) — Stock Based Compensation: 307000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Stockholders Equity: 13347000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Tangible Book Value: -8232000000.00
GSK.L income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -67625000.00
GSK.L income_statement (annual, 2023-12-31) — Tax Provision: 756000000.00
GSK.L income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.13
GSK.L balance_sheet (annual, 2023-12-31) — Taxes Receivable: 938000000.00
GSK.L cash_flow (annual, 2023-12-31) — Taxes Refund Paid: -1328000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Total Assets: 59005000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Total Capitalization: 27501000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Total Debt: 18018000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 12795000000.00
GSK.L income_statement (annual, 2023-12-31) — Total Expenses: 22983000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 46210000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 40361000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 25142000000.00
GSK.L income_statement (annual, 2023-12-31) — Total Operating Income As Reported: 6745000000.00
GSK.L income_statement (annual, 2023-12-31) — Total Other Finance Cost: 58000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Total Tax Payable: 500000000.00
GSK.L income_statement (annual, 2023-12-31) — Total Unusual Items: -541000000.00
GSK.L income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -541000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Tradeand Other Payables Non Current: 924000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 255885366.00
GSK.L balance_sheet (annual, 2023-12-31) — Work In Process: 2449000000.00
GSK.L balance_sheet (annual, 2023-12-31) — Working Capital: -2424000000.00
GSK.L cash_flow (quarterly, 2024-09-30) — Gain Loss On Sale Of Business: 0.00
GSK.L cash_flow (quarterly, 2024-09-30) — Long Term Debt Payments: 1000000.00
GSK.L balance_sheet (quarterly, 2024-09-30) — Other Investments: 1023000000.00
GSK.L balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 1940000000.00
GSK.L income_statement (quarterly, 2024-09-30) — Other Operating Expenses: 335000000.00
GSK.L income_statement (quarterly, 2024-09-30) — Special Income Charges: 0.00
GSK.L income_statement (quarterly, 2024-09-30) — Total Unusual Items: 0.00
GSK.L income_statement (quarterly, 2024-09-30) — Total Unusual Items Excluding Goodwill: 0.00
GSK.L income_statement (annual, 2024-12-31) — +Operating Expense: 16786000000.00
GSK.L income_statement (annual, 2024-12-31) — +Total Revenue: 31376000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Accounts Payable: 3462000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Accounts Receivable: 5563000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -10483000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -10483000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 3473000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -99000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -99000000.00
GSK.L cash_flow (annual, 2024-12-31) — Amortization Cash Flow: 1454000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Assets Held For Sale Current: 3000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Available For Sale Securities: 848000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Available For Sale Securities: 848000000.00
GSK.L income_statement (annual, 2024-12-31) — Basic Average Shares: 4077000000.00
GSK.L income_statement (quarterly, 2024-12-31) — Basic Average Shares: 4081000000.00
GSK.L income_statement (annual, 2024-12-31) — Basic EPS: 0.63
GSK.L income_statement (quarterly, 2024-12-31) — Basic EPS: 0.10
GSK.L cash_flow (annual, 2024-12-31) — Beginning Cash Position: 2858000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 636000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 636000000.00
GSK.L cash_flow (annual, 2024-12-31) — Capital Expenditure: -2982000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 1102000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Capital Lease Obligations: 1102000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Capital Stock: 1348000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 3693000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 3714000000.00
GSK.L cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -2444000000.00
GSK.L cash_flow (annual, 2024-12-31) — Change In Inventory: -294000000.00
GSK.L cash_flow (annual, 2024-12-31) — Change In Other Current Assets: 999000000.00
GSK.L cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: 1834000000.00
GSK.L cash_flow (annual, 2024-12-31) — Change In Payable: -789000000.00